PE20240923A1 - Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil) (metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cancer - Google Patents
Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil) (metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cancerInfo
- Publication number
- PE20240923A1 PE20240923A1 PE2023003361A PE2023003361A PE20240923A1 PE 20240923 A1 PE20240923 A1 PE 20240923A1 PE 2023003361 A PE2023003361 A PE 2023003361A PE 2023003361 A PE2023003361 A PE 2023003361A PE 20240923 A1 PE20240923 A1 PE 20240923A1
- Authority
- PE
- Peru
- Prior art keywords
- methylhexan
- diazaspiro
- octan
- triazin
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021100466 | 2021-06-17 | ||
| CN2022091677 | 2022-05-09 | ||
| PCT/CN2022/099089 WO2022262796A1 (en) | 2021-06-17 | 2022-06-16 | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240923A1 true PE20240923A1 (es) | 2024-04-30 |
Family
ID=82196389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003361A PE20240923A1 (es) | 2021-06-17 | 2022-06-16 | Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil) (metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cancer |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| KR20250170131A (ko) | 2023-04-17 | 2025-12-04 | 얀센 파마슈티카 엔브이 | 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물 |
| KR20260099138A (ko) | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| KR20260115654A (ko) | 2023-12-04 | 2026-07-24 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | 치환된 다환 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| BR112018012707A2 (pt) * | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー,インク. | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
-
2022
- 2022-06-16 AU AU2022292697A patent/AU2022292697A1/en active Pending
- 2022-06-16 KR KR1020237043027A patent/KR20240021808A/ko active Pending
- 2022-06-16 MX MX2023014890A patent/MX2023014890A/es unknown
- 2022-06-16 EP EP22733288.9A patent/EP4355747A1/en active Pending
- 2022-06-16 CN CN202280043068.0A patent/CN117597348A/zh active Pending
- 2022-06-16 JP JP2023576415A patent/JP7864745B2/ja active Active
- 2022-06-16 CA CA3220099A patent/CA3220099A1/en active Pending
- 2022-06-16 CN CN202410890382.3A patent/CN118852178A/zh active Pending
- 2022-06-16 PE PE2023003361A patent/PE20240923A1/es unknown
- 2022-06-16 WO PCT/CN2022/099089 patent/WO2022262796A1/en not_active Ceased
- 2022-06-16 PH PH1/2023/553300A patent/PH12023553300A1/en unknown
- 2022-06-16 US US18/570,727 patent/US20260125387A1/en active Pending
- 2022-06-16 IL IL309359A patent/IL309359A/en unknown
- 2022-06-17 UY UY0001039823A patent/UY39823A/es unknown
-
2023
- 2023-11-28 DO DO2023000260A patent/DOP2023000260A/es unknown
- 2023-12-13 CL CL2023003731A patent/CL2023003731A1/es unknown
- 2023-12-28 CO CONC2023/0018577A patent/CO2023018577A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202315636A (zh) | 2023-04-16 |
| WO2022262796A1 (en) | 2022-12-22 |
| KR20240021808A (ko) | 2024-02-19 |
| CL2023003731A1 (es) | 2024-07-05 |
| PH12023553300A1 (en) | 2024-04-08 |
| IL309359A (en) | 2024-02-01 |
| CO2023018577A2 (es) | 2024-01-15 |
| UY39823A (es) | 2023-01-31 |
| JP7864745B2 (ja) | 2026-05-25 |
| MX2023014890A (es) | 2024-04-29 |
| AU2022292697A1 (en) | 2024-02-01 |
| US20260125387A1 (en) | 2026-05-07 |
| CN117597348A (zh) | 2024-02-23 |
| WO2022262796A8 (en) | 2023-03-23 |
| JP2024525145A (ja) | 2024-07-10 |
| CN118852178A (zh) | 2024-10-29 |
| DOP2023000260A (es) | 2024-05-15 |
| CA3220099A1 (en) | 2022-12-22 |
| EP4355747A1 (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241728A1 (es) | Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimidin-6-il]fenil]-4-[[3(r)- [(1-oxo)-2-propen-1-il)amino]-1-piperidinil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer | |
| RU2020123241A (ru) | Полициклические соединения в качестве аллостерических ингибиторов shp2 | |
| AR068086A2 (es) | Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos | |
| DOP2023000208A (es) | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek | |
| JP2023512113A5 (cg-RX-API-DMAC7.html) | ||
| AR074876A1 (es) | Derivados de indol-pirimidina para tratar cancer | |
| AR034259A1 (es) | Polimorfos de un analogo de epotilona, procesos para prepararlos y las composiciones farmaceuticas que los contienen | |
| MX2023014890A (es) | Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2 - metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]o ctan-6-il)- 1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer. | |
| FI3768674T3 (fi) | Aminopyrimidiinijohdannaisia ctps1:n estäjinä | |
| RU2018122864A (ru) | Ингибиторы протеинкиназ, их способ получения и медицинское применение | |
| RU2015153094A (ru) | Арилхиназолины | |
| NZ710411A (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) | |
| HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
| EA200200643A1 (ru) | ПИРИДО[2,3-d]ПИРИМИДИН-2,7-ДИАМИНОВЫЕ ИНГИБИТОРЫ КИНАЗ | |
| JP2018505207A5 (cg-RX-API-DMAC7.html) | ||
| PE20201028A1 (es) | Compuestos biciclicos de pirazol y triazolo como inhibidores de las cinasas jak | |
| SI20691B (sl) | Triciklični inhibitorji poli(ADP-riboza) polimeraz | |
| ATE294185T1 (de) | Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate | |
| AR056186A1 (es) | Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende | |
| HRP20150235T1 (hr) | Derivati pirimidina, njihovo dobivanje i njihova farmaceutska upotreba | |
| JP2022500383A5 (cg-RX-API-DMAC7.html) | ||
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| EP1749830A4 (en) | CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS | |
| PE20242359A1 (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos | |
| FI4419526T3 (fi) | Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa |